CN110624116A - 一种石墨烯-稀土上转换复合纳米微球的制备方法及其应用 - Google Patents
一种石墨烯-稀土上转换复合纳米微球的制备方法及其应用 Download PDFInfo
- Publication number
- CN110624116A CN110624116A CN201910882304.8A CN201910882304A CN110624116A CN 110624116 A CN110624116 A CN 110624116A CN 201910882304 A CN201910882304 A CN 201910882304A CN 110624116 A CN110624116 A CN 110624116A
- Authority
- CN
- China
- Prior art keywords
- rare earth
- graphene
- conversion
- solution
- conversion composite
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052761 rare earth metal Inorganic materials 0.000 title claims abstract description 82
- 239000004005 microsphere Substances 0.000 title claims abstract description 51
- 238000006243 chemical reaction Methods 0.000 title claims abstract description 44
- 239000002131 composite material Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 26
- 239000010931 gold Substances 0.000 claims abstract description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 229910021389 graphene Inorganic materials 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 18
- 239000002105 nanoparticle Substances 0.000 claims abstract description 17
- 229910052737 gold Inorganic materials 0.000 claims abstract description 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000002910 rare earth metals Chemical class 0.000 claims abstract description 15
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000011068 loading method Methods 0.000 claims abstract description 11
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims abstract description 6
- 238000013329 compounding Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 239000012221 photothermal agent Substances 0.000 claims abstract description 5
- 239000002077 nanosphere Substances 0.000 claims abstract description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 60
- 206010028980 Neoplasm Diseases 0.000 claims description 35
- 229960004679 doxorubicin Drugs 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 25
- 239000007853 buffer solution Substances 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 19
- 229910052769 Ytterbium Inorganic materials 0.000 claims description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 14
- 229910021642 ultra pure water Inorganic materials 0.000 claims description 14
- 239000012498 ultrapure water Substances 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 210000000170 cell membrane Anatomy 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 11
- 238000005406 washing Methods 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 10
- 229910052691 Erbium Inorganic materials 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000003384 imaging method Methods 0.000 claims description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 6
- 239000011159 matrix material Substances 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- YTVQIZRDLKWECQ-UHFFFAOYSA-N 2-benzoylcyclohexan-1-one Chemical compound C=1C=CC=CC=1C(=O)C1CCCCC1=O YTVQIZRDLKWECQ-UHFFFAOYSA-N 0.000 claims description 5
- 230000005284 excitation Effects 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 claims description 4
- 239000012190 activator Substances 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 229910009523 YCl3 Inorganic materials 0.000 claims description 3
- 238000001027 hydrothermal synthesis Methods 0.000 claims description 3
- 238000011503 in vivo imaging Methods 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 3
- PCMOZDDGXKIOLL-UHFFFAOYSA-K yttrium chloride Chemical compound [Cl-].[Cl-].[Cl-].[Y+3] PCMOZDDGXKIOLL-UHFFFAOYSA-K 0.000 claims description 3
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 2
- 229910052689 Holmium Inorganic materials 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052779 Neodymium Inorganic materials 0.000 claims description 2
- 229910052775 Thulium Inorganic materials 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 150000002500 ions Chemical class 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 229910052727 yttrium Inorganic materials 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 2
- 239000000872 buffer Substances 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- AKXUUJCMWZFYMV-UHFFFAOYSA-M tetrakis(hydroxymethyl)phosphanium;chloride Chemical compound [Cl-].OC[P+](CO)(CO)CO AKXUUJCMWZFYMV-UHFFFAOYSA-M 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 238000004506 ultrasonic cleaning Methods 0.000 claims 1
- -1 rare earth ions Chemical class 0.000 abstract description 4
- 238000013270 controlled release Methods 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000031700 light absorption Effects 0.000 abstract description 2
- 238000004020 luminiscence type Methods 0.000 abstract description 2
- 238000012546 transfer Methods 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 238000007306 functionalization reaction Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000013267 controlled drug release Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000002114 nanocomposite Substances 0.000 description 2
- 239000002836 nanoconjugate Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000005424 photoluminescence Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 229910004042 HAuCl4 Inorganic materials 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- HDGGAKOVUDZYES-UHFFFAOYSA-K erbium(iii) chloride Chemical compound Cl[Er](Cl)Cl HDGGAKOVUDZYES-UHFFFAOYSA-K 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 238000002173 high-resolution transmission electron microscopy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 238000004729 solvothermal method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- CKLHRQNQYIJFFX-UHFFFAOYSA-K ytterbium(III) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Yb+3] CKLHRQNQYIJFFX-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0065—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle
- A61K49/0067—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the luminescent/fluorescent agent having itself a special physical form, e.g. gold nanoparticle quantum dots, fluorescent nanocrystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Materials Engineering (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明涉及一种石墨烯‑稀土上转换复合纳米微球的制备方法及其应用,属于纳米载药材料技术领域。其首先制备组氨酸功能化石墨烯量子点,然后制备石墨烯量子点‑稀土氟化物上转换复合物;对药物进行装载,最后与光热剂金纳米颗粒复合,制得石墨烯‑稀土上转换复合纳米微球。本发明利用组氨酸与稀土离子强的配位能力,实现了对稀土UCNP尺寸和形貌的有效调控;利用纳米石墨烯吸收红外光能力强及能与稀土UCNP间进行高效的能量转移,提高了稀土UCNP材料的上转换发光效率;利用纳米金对上转换发光中可见光部分的吸收产生热,实现药物的光控释放。
Description
技术领域
本发明涉及一种石墨烯-稀土上转换复合纳米微球的制备方法及其应用,属于纳米载药材料技术领域。
背景技术
镧系元素掺杂的上转换纳米粒子(UCNP)能够将近红外激发光转换为波长更短的可见光或紫外光发射。镧系元素掺杂的UCNP具有背景荧光小、光稳定性好、反斯托克斯位移大和可忽略的生物毒性,已显示出在生物医学及相关领域应用的巨大优势。然而,镧系掺杂的UCNP受到在水介质中稳定性差、功能修饰困难和上转换发光效率不高的限制。目前,广泛采用的溶剂热法所制备的镧系元素UCNP是油溶性材料,通常需要经过“脱去羧基”、“亲水性材料包覆”和“功能修饰”等环节才能用于生物医学领域的研究。材料制备过程复杂,难以规模化生产,而且载药能力十分有限,直接影响到治疗效果。由于光子上转换过程是通过辐射跃迁方式实现的,这些跃迁总是需要很长的辐射寿命,而大多数输入的能量将通过更快的非辐射衰变途径消失。为克服以上不足,研究人员对镧系元素掺杂UCNP材料制备、改性与应用进行了大量基础性研究,并取得一些突破性进展,但提高镧系元素掺杂UCNP材料的上转换发光效率和在水介质中的稳定性和载药能力仍面临极大地担战。
目前,石墨烯功能化方法主要是将石墨烯与功能材料进行简单物理混合而成。石墨烯与功能材料之间并未实现深度的融合,因此不同材料间的协同效应难以得到充分体现。为了解决以上问题,尝试一种将石墨烯和稀土材料通过共价键结合的新功能化途径。
发明内容
本发明的目的是克服上述不足之处,提供一种石墨烯-稀土上转换复合纳米微球的制备方法。
本发明设计合成组氨酸和十八胺共功能化纳米石墨烯,建立一种石墨烯-稀土凝胶纳米微球的制备方法,将其作为抗癌药物载体应用于肿瘤靶向治疗。
石墨烯的功能化是实现其广泛应用的重要前堤和基础性工作。
作为本发明的一个目的,一种石墨烯-稀土上转换复合纳米微球的制备方法,首先制备组氨酸功能化石墨烯量子点,然后制备石墨烯量子点-稀土氟化物上转换复合物;对药物进行装载,最后与光热剂金纳米颗粒复合,制得石墨烯-稀土上转换复合纳米微球。
进一步地,步骤如下:
(1)制备组氨酸功能化石墨烯量子点:将柠檬酸、组氨酸叶酸和十八胺混合物按照摩尔比1:0.5-1.5:0.001-0.01:0.001-0.01在150-220℃下水热反应1-10h,制得组氨酸功能化石墨烯量子点;
(2)制备石墨烯-稀土凝胶纳米微球:
a、采用Y或Gd作为基质,采用Yb或Nd作为敏化剂,采用Er、Tm或Ho作为激活剂进行反应;其中基质:敏化剂的摩尔比为1:2~4;敏化剂:激活剂的摩尔比为1:3~5;
首先将上述稀土混合物溶解于超纯水中,随后滴加His/FA/OA-NG的水溶液进行反应,洗涤后得到石墨烯-稀土配合物;所述稀土混合物:His-OA-NG的质量比为1:3-10;
b、将石墨烯-稀土配合物分散在超纯水中,加入NaF水溶液,使得稀土元素:F离子摩尔比为1:4;继续搅拌50-70min,然后转移到压力反应器中,在150-250℃下加热反应3-24h,冷却至室温,过滤,收集上清液;
c、对步骤b所得上清液以10000-30000rpm离心10-60min;将收集到的沉淀物水洗涤1-10次,得到石墨烯-稀土凝胶纳米微球固体样品,然后重新分散在超纯水中形成1.8-2.2mgmL-1溶液,并储存在4℃的冰箱中备用;
(3)装载药物:将1mg.mL-1多柔比星DOX溶液加入到步骤(3)所得的石墨烯-稀土凝胶纳米微球中,其中石墨烯-稀土凝胶纳米微球:DOX溶液的质量比为1:1-10;室温搅拌过夜,离心、缓冲溶液洗涤,以除去过量的非特异性结合的DOX,得到的复合物再分散于缓冲溶液中;
(4)与光热剂金纳米颗粒复合:
a、将12μL的80%四羟甲基氯化鏻THPC和0.25 mL的2mol L-1 NaOH加入到45mL水中;将混合物剧烈搅拌5分钟,然后快速注入2.0mL质量浓度为1%的HAuCl4,观察到颜色立即变为深棕色,将该溶液储存在遮光的容器中搅拌过夜,得到备用的金纳米粒子溶液;
b、将金纳米粒子溶液与装载DOX的石墨烯-稀土凝胶纳米微球在缓冲溶液中混合,其金纳米粒子溶液:石墨烯-稀土凝胶纳米微球的质量比为1:2-10;在36-38℃下反应75-85min,离心分离,得到石墨烯-稀土凝胶纳米微球复合物固体;
c、将得到的石墨烯-稀土凝胶纳米微球复合物固体重新分散在200μL含有5 mmol L-1MgCl2和50 mmol L-1 NaCl的缓冲溶液中,即得到石墨烯-稀土上转换复合纳米微球。
(5)包裹入癌细胞膜中
从癌细胞中获得所需癌细胞膜作为外壳。将癌细胞在0-10℃下用高渗透Tris缓冲液(pH=7.4)进行处理,用均质机在20,000-30,000rpm下使其彻底破碎,并以400-600×g离心10分钟去除细胞内物质。将上清液以10,000×g离心10分钟并以100,000×g离心1小时以获得细胞膜沉淀。用PBS洗涤沉淀,并在超声清洗机中超声处理5秒。最后通过200-400nm聚碳酸酯膜进行最后筛选。
将步骤(4)中所得石墨烯-稀土上转换复合纳米微球与癌细胞膜混合,形成囊泡结构。
进一步地,步骤(1)a中,以Y作为基质, Yb作为敏化剂, Er作为激活剂进行反应具体过程如下:将YCl3、YbCl3和ErCl3溶解在10mL超纯水中,保证Y:Yb摩尔比为1:2.0-4.0,Yb:Er摩尔比为1:3-5;滴加50mg.mL-1 His/FA/OA-NG的水溶液,其中稀土总质量:His-OA-NG质量比为1:3-10;收集产生的沉淀物,超纯水洗涤二次去除游离的His/FA/OA-NG,得到石墨烯-稀土配合物。
进一步地,步骤(3)所述缓冲液为含有0.2 mol L-1 NaCl的10mmol L-1 的Tris-HCl缓冲溶液;
步骤(4)中步骤b所述缓冲液具体为含有5 mmol L-1 MgCl2, 50 mmol L-1 NaCl的pH7.4、20mmol L-1 Tris-HCl缓冲溶液;
步骤(4)中步骤c中的缓冲液为pH 7.4、20 mmol L-1的Tris-HCl缓冲溶液。
步骤(5)中的癌细胞为目标癌症所对应的癌细胞。
作为本发明的另一个目的,石墨烯-稀土上转换复合纳米微球的应用,将其应用于成像中。
进一步地,将石墨烯-稀土上转换复合纳米微球注射入待检测部位,使用配备有980 nm光纤耦合激光的体内成像系统成像;在曝光时间为30秒的成像期间,激光功率密度为290-300mW/cm2,应用790/40nm带通发射滤光器以防止激发光对CCD相机的干扰。
进一步地,将其应用于体内药物光控释放中。
进一步地,将石墨烯-稀土上转换复合纳米微球注射入待检测部位,使用配备有980 nm光纤耦合激光照射,持续5分钟,照射1分钟后间隔1分钟。
本发明的有益效果:本发明利用纳米石墨烯良好的水溶性,提高稀土UCNP材料在水介质中的稳定性;利用纳米石墨烯片大的比面积,增加稀土UCNP材料的载药量;利用组氨酸与稀土离子强的配位能力,实现对稀土UCNP尺寸和形貌的有效调控;利用纳米石墨烯吸收红外光能力强及能与稀土UCNP间进行高效的能量转移,提高稀土UCNP材料的上转换发光效率。
附图说明
图1是石墨烯-稀土上转换复合纳米微球的材料表征图。
a、SEM图;b、多个微球TEM图;c、单个微球TEM图;d、STEM图;e、高分辨TEM图像;
图2-a元素含量分析图。
图2-b元素含量柱状图。
图3药物负载量-载物药量比关系图。
图4相关物质紫外吸收光谱。
图5复合物的光致发光响应曲线。
图6激光共聚焦显微镜图;左图为明场光学图,右图为荧光图像。
图7小鼠成像图。
图8药物释放率-时间曲线。
图9为药物释放量和荧光关系示意图。
图10为负载了DOX的纳米复合物瘤内注射到小鼠肿瘤部位示意图。
具体实施方式
实施例1
(1)制备组氨酸功能化石墨烯量子点:
组氨酸和功能化石墨烯量子点通过将柠檬酸、组氨酸和十八胺混合物在180°C下水热反应4小时制得。
(2)制备石墨烯量子点-稀土氟化物上转换复合物:
将YCl3(7.5 mmol)、YbCl3(2.0 mmol)和ErCl3(0.5 mmol)溶解在超纯水(10 mL)中,滴加His/FA/OA-NG水溶液(50 mg mL-1,100 mL),收集产生的沉淀物,超纯水洗涤二次去除游离的His/FA/OA-NG,得到石墨烯-稀土配合物。将此石墨烯-稀土配合物分散在超纯水(10mL)中,加入NaF水溶液(1.0 mol L-1,120 mL),继续搅拌60分钟,然后转移到压力反应器中,在180°C下加热反应4小时,冷却至室温。
为了获得石墨烯-稀土凝胶纳米微球(His/FA/OA-NG-NaYF4:Yb,Er),将收集到的上清液以15000 rpm离心分离20分钟。将收集到的沉淀物水洗涤3次,得到His/FA/OA-NG-NaYF4:Yb,Er固体样品,然后重新分散在超纯水中形成2.0 mg mL-1溶液,并储存在4°C的冰箱中备用。
如图1(a-e)和图2(a-b)所示,通过场发射扫描电子显微镜和球差校正高分辨透射电镜对材料形貌和元素分布进行表征。所获石墨烯-稀土凝胶纳米微球呈现球状结构,且均匀的分散,平均直径为约57.2 nm,中间呈现出多孔网络结构。元素分析图表明出C,N,Y和Yb均匀分布,具有高结晶度,层间距为0.22 nm归因于石墨烯的(100)晶格间距。
(3)装载药物:
将50 μL多柔比星(DOX)溶液(1 mg mL-1)加入到His/FA/OA-NG-NaYF4:Yb,Er溶液中,室温搅拌过夜,然后离心15分钟,用缓冲溶液(0.2 mol L-1 NaCl,10 mmol L-1 Tris-HCl)洗涤以除去过量的非特异性结合的DOX,得到的复合物再分散于含有0.2 mol L-1 NaCl的10mmol L-1 Tris-HCl缓冲溶液。
将His/FA/OA-NG-NaYF4:Yb,Er复合物与DOX以一定的质量比(从上到下:0、0.02、0.04、0.1、0.2、0.4和1)分散在超纯水中并充分混合搅拌使它们充分接触。搅拌过夜后,离心(15000 rpm,10 min)收集沉淀并洗涤提纯。将上层清液与初始浓度的DOX溶液进行紫外检测,得到图3(双光束紫外可见分光光度计TU-1901)。在480 nm处所得峰来自于DOX的响应,其峰值的变化可以说明未负载的DOX含量的变化。当复合物与DOX的质量比为1:1时,紫外峰值最低可以说明其负载量最高。
为了证明DOX和Au确实成功负载进His/FA/OA-NG-NaYF4:Yb,Er复合物中,而不是仅仅混合在沉淀中,将His/FA/OA-NG-NaYF4:Yb,Er、DOX、Au和His/FA/OA-NG-NaYF4:Yb,Er@DOX@Au配成相同摩尔浓度的水溶液,利用紫外吸收光谱测定它们的特征吸收。如图4所示(双光束紫外可见分光光度计TU-1901),His/FA/OA-NG-NaYF4:Yb,Er的特征峰位于298 nm,DOX的特征峰位于490 nm。而His/FA/OA-NG-NaYF4:Yb,Er@DOX@Au的光谱中也可发现这两个特征峰,这可以推论DOX已被成功负载进入His/FA/OA-NG-NaYF4:Yb,Er复合物中。
(4)与光敏金纳米颗粒复合:
将12 μL的80%四羟甲基氯化鏻(THPC)和0.25 mL的2 mol L-1 NaOH加入到45 mL水中。将混合物剧烈搅拌5分钟,然后快速注入2.0 mL的1% HAuCl4。观察到颜色立即变为深棕色。将该溶液储存在遮光的容器中搅拌过夜。将Au纳米颗粒溶液(100 μL)与装载DOX的His/FA/OA-NG-NaYF4:Yb,Er溶液(40 μL)在20 mmol L-1 Tris-HCl缓冲溶液(pH 7.4, 5mmol L-1 MgCl2, 50 mmol L-1 NaCl)中混合,总体积为200 μL。在37°C下反应80分钟,离心分离,得到His/FA/OA-NG-NaYF4:Yb,Er@DOX复合物固体。将得到的固体样重新分散在200 μL含有5 mmol L-1 MgCl2和50 mmol L-1 NaCl的Tris-HCl缓冲溶液(pH 7.4, 20 mmol L-1)中。
图5所示,纳米复合物在紫外-可见范围内的发射强度随着Au含量的增加呈下降趋势(荧光分光光度计CARY Eclipse)。当Au与Y的摩尔比超过1.4时,发射峰几乎都完全消失。在紫外-可见区域中上转换发射的猝灭,可能通过局部光热效应导致Au纳米颗粒的表面温度增加。由此,Au纳米颗粒吸收的光将以热量释放。
通过图6激光共聚焦显微镜图(激光共聚焦显微镜LSM710),在加金和不加金后,2小时所得的明场光学图像和荧光图像也可说明金纳米颗粒对荧光有猝灭作用。
(5)包裹入癌细胞膜中
将HepG2肝癌细胞在4℃下用高渗透Tris缓冲液(pH=7.4)进行处理,用均质机在22000rpm下使其彻底破碎,并以500×g离心10分钟去除细胞内物质。将上清液以10000×g离心10分钟并以100,000×g离心1小时以获得细胞膜沉淀。用PBS洗涤沉淀,并在超声清洗机中超声处理5秒。最后通过400nm和200nm聚碳酸酯膜进行最后筛选。
将步骤(4)中所得石墨烯-稀土上转换复合纳米微球与A549癌细胞膜混合,形成囊泡结构。
应用实施例1 小鼠成像
将含有His-GQD-OA-NaYF4:Yb,Er@DOX@Au纳米复合物的缓冲溶液(60 μL,0.2 mol L-1NaCl,10 mmol L-1 Tris-HCl)皮下注射进裸鼠的肿瘤部位。使用配备有980 nm光纤耦合激光的体内成像系统对小鼠成像。在曝光时间为30秒的成像期间,激光功率密度约为299.9mW/cm2(电流4.2 A,功率为212 mW)。应用790/40 nm带通发射滤光器以防止激发光对CCD相机的干扰。
图7是激光照射一小时内的肿瘤成像结果,可以看出荧光信号随着照射时间推移而增强,尤其是被激光束照射的肿瘤中心位置荧光强度最强。结果说明此纳米石墨烯/稀土复合物药物载体可被应用于生物成像。
应用实施例2 HepG2细胞内药物光控释放
通过980 nm激光(3 W/cm-1)照射负载DOX的复合物溶液10分钟,离心分离,收集含有释放DOX分子的上清液,然后在荧光光度计上测定DOX的特征荧光发射,以此计算药物释放率。
图8中与时间相关的光致发光研究表明,当光照时间超过60分钟后,药物的释放趋于缓慢,最大释放含量大约为80%。
将HepG2细胞接种在培养皿(35mm)中,并在DMEM培养基中培养1天(5%CO2, 37°C)。随后,用含有100 μLCGYAu复合物、DOX和CGYAu-DOX的新鲜1mL DMEM培养基替换之前的培养基。孵育3小时(5%CO2, 37℃)后,用1mL PBS洗涤细胞两次,并用Hoechst 33342对细胞核进行染色。其中CGYAu-DOX为两份,一份用980nm激光照射15分钟,一份不用激光照射。曝光后,用配备有激发滤光片(535nm/50nm)和发射滤光片(610 nm/75 nm)的共聚焦荧光显微镜(Nikon,Eclipse TE2000-E)获得荧光成像。
图9A中显示CGYAu-DOX+NIR具有最大的药物释放量,说明复合物有助于药物传递,并且在激光照射后效果显著,证明可实现对癌细胞的光热控制药物释放。图9B中对荧光密度进行分析,可得随时间增加释放量增加。
应用实施例2 小鼠体内药物光控释放
携带HepG2肿瘤的Balb/c裸鼠(年龄4-6周,体重18 g),首先通过腹膜内注射氯胺酮麻醉(150 mg/kg)/甲苯噻嗪(10 mg/kg)。将含瘤小鼠随机分为4组(每组n≥6)。对于治疗组,在肿瘤部位向含瘤小鼠注射负载DOX的纳米复合物,然后用980 nm激光照射(500 mW/cm2,持续5分钟,照射1分钟后间隔1分钟)。三组小鼠用作对照。
对照1,仅激光照射(500 mW/cm2持续5分钟,照射1分钟后间隔1分钟);
对照2,没有激光照射和纳米缀合物的处理;
对照3,处理负载DOX的纳米缀合物(50 μL)但没有激光照射。
每2天使用游标卡尺测量肿瘤大小。根据公式V = L×W2/2计算肿瘤体积(V),其中L和W分别是肿瘤的长度和宽度。
图10将负载了DOX的纳米复合物瘤内注射到小鼠肿瘤部位,然后进行980 nm激光照射,治疗后每3天测量肿瘤大小。经过药物注射和近红外激光照射后肿瘤的大小逐渐减小,表明药物成功释放到肿瘤部位。
Claims (8)
1.一种石墨烯-稀土上转换复合纳米微球的制备方法,其特征是:首先制备组氨酸功能化石墨烯量子点,然后制备石墨烯量子点-稀土氟化物上转换复合物;对药物进行装载,最后与光热剂金纳米颗粒复合,制得石墨烯-稀土上转换复合纳米微球。
2.如权利要求1所述石墨烯-稀土上转换复合纳米微球的制备方法,其特征是步骤如下:
(1)制备组氨酸功能化石墨烯量子点:将柠檬酸、组氨酸、叶酸和十八胺混合物按照摩尔比1:0.5-1.5:0.001-0.01:0.001-0.01在150-220℃下水热反应1-10h,制得组氨酸功能化石墨烯量子点;
(2)制备石墨烯-稀土凝胶纳米微球:
a、采用Y或Gd作为基质,采用Yb或Nd作为敏化剂,采用Er、Tm或Ho作为激活剂进行反应;其中基质:敏化剂的摩尔比为1:2-4;敏化剂:激活剂的摩尔比为1:3-5;
首先将上述稀土混合物溶解于超纯水中,随后滴加His/FA/OA-NG的水溶液进行反应,洗涤后得到石墨烯-稀土配合物;所述稀土混合物:His-OA-NG的质量比为1:3-10;
b、将石墨烯-稀土配合物分散在超纯水中,加入NaF水溶液,使得稀土元素:F离子摩尔比为1:4;继续搅拌50-70min,然后转移到压力反应器中,在150-250℃下加热反应3-24h,冷却至室温,过滤,收集上清液;
c、对步骤b所得上清液以10000-30000rpm离心10-60min;将收集到的沉淀物水洗涤1-10次,得到石墨烯-稀土凝胶纳米微球固体样品,然后重新分散在超纯水中形成1.8-2.2mgmL-1溶液,并储存在4℃的冰箱中备用;
(3)装载药物:将1mg.mL-1多柔比星DOX溶液加入到步骤(3)所得的石墨烯-稀土凝胶纳米微球中,其中石墨烯-稀土凝胶纳米微球:DOX溶液的质量比为1:1-10;室温搅拌过夜,离心、缓冲溶液洗涤,以除去过量的非特异性结合的DOX,得到的复合物再分散于缓冲溶液中;
(4)与光热剂金纳米颗粒复合:
a、将12μL的80%四羟甲基氯化鏻THPC和0.25 mL的2mol L-1 NaOH加入到45mL水中;将混合物剧烈搅拌5分钟,然后快速注入2.0mL质量浓度为1%的HAuCl4,观察到颜色立即变为深棕色,将该溶液储存在遮光的容器中搅拌过夜,得到备用的金纳米粒子溶液;
b、将金纳米粒子溶液与装载DOX的石墨烯-稀土凝胶纳米微球在缓冲溶液中混合,其金纳米粒子溶液:石墨烯-稀土凝胶纳米微球的质量比为1:2-10;在36-38℃下反应75-85min,离心分离,得到石墨烯-稀土凝胶纳米微球复合物固体;
c、将得到的石墨烯-稀土凝胶纳米微球复合物固体重新分散在200μL含有5 mmol L-1MgCl2和50 mmol L-1 NaCl的缓冲溶液中,即得到石墨烯-稀土上转换复合纳米微球;
(5)包裹入癌细胞膜中:从癌细胞中获得所需癌细胞膜作为外壳,将癌细胞在0-10℃下用pH=7.4的高渗透Tris缓冲液进行处理,用均质机在20000-30000rpm下使其彻底破碎,并以400-600×g离心10分钟去除细胞内物质;将上清液以10000×g离心10分钟并以100000×g离心1小时以获得细胞膜沉淀;用PBS洗涤沉淀,并在超声清洗机中超声处理5秒,最后通过200-400nm聚碳酸酯膜进行最后筛选;将步骤(4)中所得石墨烯-稀土上转换复合纳米微球与癌细胞膜混合,形成囊泡结构。
3.如权利要求2所述石墨烯-稀土上转换复合纳米微球的制备方法,其特征是步骤(1)a中,以Y作为基质, Yb作为敏化剂, Er作为激活剂进行反应具体过程如下:将YCl3、YbCl3和ErCl3溶解在10mL超纯水中,保证Y:Yb摩尔比为1:2.0-4.0,Yb:Er摩尔比为1:3-5;滴加50mg.mL-1 His/FA/OA-NG的水溶液,其中稀土总质量:His-OA-NG质量比为1:3-10;收集产生的沉淀物,超纯水洗涤二次去除游离的His/FA/OA-NG,得到石墨烯-稀土配合物。
4.如权利要求2所述石墨烯-稀土上转换复合纳米微球的制备方法,其特征是:步骤(3)所述缓冲液为含有0.2 mol L-1 NaCl的10mmol L-1 的Tris-HCl缓冲溶液;
步骤(4)中步骤b所述缓冲液具体为含有5 mmol L-1 MgCl2, 50 mmol L-1 NaCl的pH7.4、20mmol L-1 Tris-HCl缓冲溶液;
步骤(4)中步骤c中的缓冲液为pH 7.4、20 mmol L-1的Tris-HCl缓冲溶液;
步骤(5)中的癌细胞为目标癌症所对应的癌细胞。
5.石墨烯-稀土上转换复合纳米微球的应用,其特征是:将其应用于成像中。
6.如权利要求4所述石墨烯-稀土上转换复合纳米微球的应用,其特征是:将石墨烯-稀土上转换复合纳米微球注射入待检测部位,使用配备有980 nm光纤耦合激光的体内成像系统成像;在曝光时间为30秒的成像期间,激光功率密度为290-300mW/cm2,应用790/40nm带通发射滤光器以防止激发光对CCD相机的干扰。
7.石墨烯-稀土上转换复合纳米微球的应用,其特征是:将其应用于体内药物光控释放中。
8.如权利要求7所述石墨烯-稀土上转换复合纳米微球的应用,其特征是:将石墨烯-稀土上转换复合纳米微球注射入待检测部位,使用配备有980 nm光纤耦合激光照射,持续5分钟,照射1分钟后间隔1分钟。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910882304.8A CN110624116B (zh) | 2019-09-18 | 2019-09-18 | 一种石墨烯-稀土上转换复合纳米微球的制备方法及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910882304.8A CN110624116B (zh) | 2019-09-18 | 2019-09-18 | 一种石墨烯-稀土上转换复合纳米微球的制备方法及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110624116A true CN110624116A (zh) | 2019-12-31 |
CN110624116B CN110624116B (zh) | 2021-11-12 |
Family
ID=68971180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910882304.8A Active CN110624116B (zh) | 2019-09-18 | 2019-09-18 | 一种石墨烯-稀土上转换复合纳米微球的制备方法及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110624116B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111701029A (zh) * | 2020-07-10 | 2020-09-25 | 济南康硕生物技术有限公司 | 一种上转换仿生复合体及制备方法和弱紫外转换的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107137723A (zh) * | 2017-05-04 | 2017-09-08 | 上海大学 | 一种用于多模态诊疗一体化的纳米体系及其制备方法与应用 |
CN108410465A (zh) * | 2018-03-16 | 2018-08-17 | 江南大学 | 荧光增强型石墨烯量子点-下转换稀土氟化物复合材料 |
CN109468128A (zh) * | 2018-12-18 | 2019-03-15 | 江南大学 | 一种石墨烯量子点-稀土上转换纳米复合材料及其制备方法和应用 |
WO2019071258A1 (en) * | 2017-10-06 | 2019-04-11 | The Regents Of The University Of California | SELF-ASSEMBLED MICROCAPSULES FOR ENCAPSULATION AND OPTICALLY CONTROLLED CARGO DELIVERY |
-
2019
- 2019-09-18 CN CN201910882304.8A patent/CN110624116B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107137723A (zh) * | 2017-05-04 | 2017-09-08 | 上海大学 | 一种用于多模态诊疗一体化的纳米体系及其制备方法与应用 |
WO2019071258A1 (en) * | 2017-10-06 | 2019-04-11 | The Regents Of The University Of California | SELF-ASSEMBLED MICROCAPSULES FOR ENCAPSULATION AND OPTICALLY CONTROLLED CARGO DELIVERY |
CN108410465A (zh) * | 2018-03-16 | 2018-08-17 | 江南大学 | 荧光增强型石墨烯量子点-下转换稀土氟化物复合材料 |
CN109468128A (zh) * | 2018-12-18 | 2019-03-15 | 江南大学 | 一种石墨烯量子点-稀土上转换纳米复合材料及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
LI RUIYI ET AL: "Graphene quantum dot-rare earth upconversion nanocages with extremely high efficiency of upconversion luminescence, stability and drug loading towards controlled delivery and cancer theranostics", 《CHEMICAL ENGINEERING JOURNAL》 * |
LIN CUI ET AL: "Advances in the integration of quantum dots with various nanomaterials for biomedical and environmental applications", 《ANALYST》 * |
刘玲 等: "His.CDs@NaTbF4的合成及其在组氨酸检测和肿瘤细胞成像中的应用", 《无机化学学报》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111701029A (zh) * | 2020-07-10 | 2020-09-25 | 济南康硕生物技术有限公司 | 一种上转换仿生复合体及制备方法和弱紫外转换的应用 |
CN111701029B (zh) * | 2020-07-10 | 2022-08-16 | 济南康硕生物技术有限公司 | 一种上转换仿生复合体及制备方法和弱紫外转换的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN110624116B (zh) | 2021-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Current advances in lanthanide‐doped upconversion nanostructures for detection and bioapplication | |
Du et al. | Nanocomposites based on lanthanide-doped upconversion nanoparticles: diverse designs and applications | |
Li et al. | Carbon dot-silica nanoparticle composites for ultralong lifetime phosphorescence imaging in tissue and cells at room temperature | |
Fan et al. | Exploiting lanthanide-doped upconversion nanoparticles with core/shell structures | |
Shen et al. | Engineering the upconversion nanoparticle excitation wavelength: cascade sensitization of tri‐doped upconversion colloidal nanoparticles at 800 nm | |
Chen et al. | Light upconverting core–shell nanostructures: nanophotonic control for emerging applications | |
Li et al. | Highly efficient lanthanide upconverting nanomaterials: progresses and challenges | |
Zhang | Photon upconversion nanomaterials | |
Li et al. | Lab on upconversion nanoparticles: optical properties and applications engineering via designed nanostructure | |
Shen et al. | Lanthanide-doped upconverting luminescent nanoparticle platforms for optical imaging-guided drug delivery and therapy | |
Xiao et al. | Porous Pd nanoparticles with high photothermal conversion efficiency for efficient ablation of cancer cells | |
Rostami et al. | Breakthroughs in medicine and bioimaging with up-conversion nanoparticles | |
Ju et al. | An upconversion nanoprobe operating in the first biological window | |
Chien et al. | NIR‐responsive nanomaterials and their applications; upconversion nanoparticles and carbon dots: a perspective | |
Wang et al. | Rare earth fluorides upconversion nanophosphors: from synthesis to applications in bioimaging | |
Huang et al. | 915 nm light‐triggered photodynamic therapy and MR/CT dual‐modal imaging of tumor based on the nonstoichiometric Na0. 52YbF3. 52: Er upconversion nanoprobes | |
Chan et al. | Advanced sensing, imaging, and therapy nanoplatforms based on Nd 3+-doped nanoparticle composites exhibiting upconversion induced by 808 nm near-infrared light | |
CN108130069B (zh) | 稀土上转换纳米诊疗剂及其制备方法 | |
Venkatachalam et al. | Er 3+‐Doped Y 2 O 3 Nanophosphors for Near‐Infrared Fluorescence Bioimaging Applications | |
Li et al. | Highly controllable synthesis of near-infrared persistent luminescence SiO 2/CaMgSi 2 O 6 composite nanospheres for imaging in vivo | |
Pu et al. | Recent progress in the green synthesis of rare-earth doped upconversion nanophosphors for optical bioimaging from cells to animals | |
Peng et al. | Synthesis strategies and biomedical applications for doped inorganic semiconductor nanocrystals | |
Chhetri et al. | Recent advancements in Ln‐ion‐based upconverting nanomaterials and their biological applications | |
CN110408377B (zh) | 一种稀土掺杂NaCeF4近红外荧光纳米探针及其制备方法和生物应用 | |
CN110624116B (zh) | 一种石墨烯-稀土上转换复合纳米微球的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |